{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:36Z","timestamp":1740134856122,"version":"3.37.3"},"reference-count":9,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,19]]},"DOI":"10.1182\/blood.2020008250","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:46:29Z","timestamp":1607028389000},"page":"2362-2364","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Hodgkin lymphoma: outsmarting HRS cells"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"first","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020120315410291400_B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","author":"Bartlett","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2020120315410291400_B2","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2020120315410291400_B3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2020120315410291400_B4","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"2 suppl 5","key":"2020120315410291400_B5","first-page":"38","article-title":"ABVD in the treatment of Hodgkin\u2019s disease","volume":"19","author":"Bonfante","year":"1992","journal-title":"Semin Oncol"},{"issue":"21","key":"2020120315410291400_B6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"2020120315410291400_B7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V73.1.340.340","article-title":"Successful treatment of refractory Hodgkin\u2019s disease by high-dose combination chemotherapy and autologous bone marrow transplantation","volume":"73","author":"Gribben","year":"1989","journal-title":"Blood"},{"issue":"8","key":"2020120315410291400_B8","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V73.8.2086.2086","article-title":"Treatment of progressive Hodgkin\u2019s disease with intensive chemoradiotherapy and autologous bone marrow transplantation","volume":"73","author":"Phillips","year":"1989","journal-title":"Blood"},{"issue":"24","key":"2020120315410291400_B9","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease [published correction appears in N Engl J Med. 2005;353(7):744]","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/21\/2362\/1790148\/bloodbld2020008250c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/21\/2362\/1790148\/bloodbld2020008250c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:46:34Z","timestamp":1607028394000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/21\/2362\/474155\/Hodgkin-lymphoma-outsmarting-HRS-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":9,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,11,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008250","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}